ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8⁺ T Cell Cytotoxicity

Figure 4

ATXN2 increased the expression of PD-L1. (a) Correlation analysis of ATXN2 expression and immune cell infiltration. (b, c) Protein and mRNA levels of PD-L1 in SGC7901 cells (b) and SGC7901/5-FU cells (c). (d) Protein and mRNA levels of PD-L1 in SGC7901 cells overexpressing ATXN2 or treated with an AKT inhibitor. (e) Flow cytometric analysis of PD-L1 expression in SGC7901 cells overexpressing ATXN2 or treated with an AKT inhibitor. (f) Coculture of CD8⁺ T cells and tumor cells. (g) ATXN2 was overexpressed in SGC7901 cells treated with an AKT inhibitor and cocultured with CD8⁺ T cells. The survival rates of SGC7901 and SGC7901-ATXN2 cells were measured. (h) SGC7901-overexpressing ATXN2 cells were treated with an AKT inhibitor or nivolumab and cocultured with CD8⁺ T cells. The survival rate of SGC7901-ATXN2 cells was measured. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)